Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.

Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.

A non-aqueous electrolyte for a lithium-ion battery and a lithium-ion battery. The non-aqueous electrolyte includes an unsaturated phosphate compound and a cyclic unsaturated carboxylic anhydride compound. The unsaturated phosphate compound has a structure represented by structural formula (4). R.sub.13, R.sub.11 and R.sub.12 are each independently selected from a hydrocarbon group having 1 to 5 carbon atoms, and at least one of R.sub.13, R.sub.11 and R.sub.12 is an unsaturated hydrocarbon group having a double bond or a triple bond. The unsaturated cyclic carboxylic anhydride compound having a structure represented by Structural Formula 5. R.sub.14 is selected from the group consisting of an alkenylene group having 2 to 4 carbon atoms or a fluorinated alkenylene group having 2 to 4 carbon atoms. By means of the synergistic effect of two compounds, the non-aqueous electrolyte has excellent high-temperature cycling performance and storage performance, and also has lower impedance and good low-temperature performance. ##STR00001##

Diphosphites having an open, 3-methylated outer unit and use thereof in hydroformylation.

A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1):

##STR00001##

wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.

A non-aqueous electrolyte for a lithium-ion battery and a lithium-ion battery. The non-aqueous electrolyte includes an unsaturated phosphate compound and a cyclic unsaturated carboxylic anhydride compound. The unsaturated phosphate compound has a structure represented by structural formula (4). R.sub.13, R.sub.11 and R.sub.12 are each independently selected from a hydrocarbon group having 1 to 5 carbon atoms, and at least one of R.sub.13, R.sub.11 and R.sub.12 is an unsaturated hydrocarbon group having a double bond or a triple bond. The unsaturated cyclic carboxylic anhydride compound having a structure represented by Structural Formula 5. R.sub.14 is selected from the group consisting of an alkenylene group having 2 to 4 carbon atoms or a fluorinated alkenylene group having 2 to 4 carbon atoms. By means of the synergistic effect of two compounds, the non-aqueous electrolyte has excellent high-temperature cycling performance and storage performance, and also has lower impedance and good low-temperature performance.

##STR00001##

A medical lubricant may comprise a base oil. The medical lubricant can be used on a surgical device.

A hydroxyapatite particle having a plurality of functionalities on a surface, a process for forming a hydroxyapatite particle having a plurality of functionalities on a surface, and an article of manufacture including a hydroxyapatite particle having a plurality of functionalities on a surface are disclosed. The hydroxyapatite particle includes a first functionality on a first surface of the hydroxyapatite particle, where the first functionality includes first moieties to bind to polymer constructs, and a second functionality on a second surface of the hydroxyapatite particle. The process for forming the hydroxyapatite particle includes providing one or more hydroxyapatite particles, forming one or more wax particles, functionalizing a first exposed surface of the one or more hydroxyapatite particles, removing the one or more hydroxyapatite particles from the wax core, and functionalizing the second exposed surface of the one or more hydroxyapatite particles.

A hydroxyapatite particle having a plurality of functionalities on a surface, a process for forming a hydroxyapatite particle having a plurality of functionalities on a surface, and an article of manufacture including a hydroxyapatite particle having a plurality of functionalities on a surface are disclosed. The hydroxyapatite particle includes a first functionality on a first surface of the hydroxyapatite particle, where the first functionality includes first moieties to bind to polymer constructs, and a second functionality on a second surface of the hydroxyapatite particle. The process for forming the hydroxyapatite particle includes providing one or more hydroxyapatite particles, forming one or more wax particles, functionalizing a first exposed surface of the one or more hydroxyapatite particles, removing the one or more hydroxyapatite particles from the wax core, and functionalizing the second exposed surface of the one or more hydroxyapatite particles.

Ionizable compounds, and compositions and methods of use thereof. The ionizable compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, the compounds, compositions and methods are to provide nanoparticles to encapsulate active agents, such as nucleic acid agents, and to deliver and distribute the active agents to cells, tissues, organs, and subjects.